Landscape of brain myeloid cell transcriptome along the spatiotemporal progression of Alzheimer's disease reveals distinct sequential responses to Aβ and tau
Astrid Wachter,Maya E Woodbury,Sylvia Lombardo,Aicha Abdourahman,Carolin Wuest,Emily McGlame,Timothy Pastika,Joseph Tamm,Nandini Romanul,Kiran Yanamandra,Rachel Bennett,Gen Lin,Taekyung Kwon,Fan Liao,Corinna Klein,Yelena Grinberg,Methasit Jaisa-Aad,Huan Li,Matthew P Frosch,Markus P Kummer,Sudeshna Das,Tammy Dellovade,Eric H Karran,Xavier Langlois,Janina S Ried,Alberto Serrano-Pozo,Robert V Talanian,Knut Biber,Bradley T Hyman
DOI: https://doi.org/10.1007/s00401-024-02704-2
2024-04-01
Abstract:Human microglia are critically involved in Alzheimer's disease (AD) progression, as shown by genetic and molecular studies. However, their role in tau pathology progression in human brain has not been well described. Here, we characterized 32 human donors along progression of AD pathology, both in time-from early to late pathology-and in space-from entorhinal cortex (EC), inferior temporal gyrus (ITG), prefrontal cortex (PFC) to visual cortex (V2 and V1)-with biochemistry, immunohistochemistry, and single nuclei-RNA-sequencing, profiling a total of 337,512 brain myeloid cells, including microglia. While the majority of microglia are similar across brain regions, we identified a specific subset unique to EC which may contribute to the early tau pathology present in this region. We calculated conversion of microglia subtypes to diseased states and compared conversion patterns to those from AD animal models. Targeting genes implicated in this conversion, or their upstream/downstream pathways, could halt gene programs initiated by early tau progression. We used expression patterns of early tau progression to identify genes whose expression is reversed along spreading of spatial tau pathology (EC > ITG > PFC > V2 > V1) and identified their potential involvement in microglia subtype conversion to a diseased state. This study provides a data resource that builds on our knowledge of myeloid cell contribution to AD by defining the heterogeneity of microglia and brain macrophages during both temporal and regional pathology aspects of AD progression at an unprecedented resolution.